CCL2 and neoplasm: Gemcitabine drug-resistant Gal-3-high tumor cells can increase the expression of CCL2 and BSG in TAFs through the Ca2+–calcineurin–NFAT pathway, thereby leading to mitochondrial oxidative phosphorylation suspension via CCL2–CCR2 cell signaling.